Replies to post #375727 on NorthWest Biotherapeutics Inc (NWBO)

[JerryCampbell]

I don't think you can say there is a typical case, but rather that each resolution is distinct. Consider nwbo's R/S events:

In 2012, they split 1:16. Common share authorization remained constant at 450m rather than reduced, and the resolution raised the Preferred authorization from 20m to 40m.

In 2007, nwbo split 1:15. Common share authorization was reduced from 800m to 100m, a factor of 8 rather than matching the split factor of 15. Preferred authorization was divided by 15.

I agree that no R/S event is imminent since none is on the proxy for May 18. That also makes it unlikely that there is any reality to the uplist speculation.